Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma.

Mann GJ, Pupo GM, Campain AE, Carter CD, Schramm SJ, Pianova S, Gerega SK, De Silva C, Lai K, Wilmott JS, Synnott M, Hersey P, Kefford RF, Thompson JF, Yang YH, Scolyer RA.

J Invest Dermatol. 2013 Feb;133(2):509-17. doi: 10.1038/jid.2012.283. Epub 2012 Aug 30.

2.

NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA.

Cancer. 2012 Aug 15;118(16):4014-23. doi: 10.1002/cncr.26724. Epub 2011 Dec 16.

3.

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.

Bucheit AD, Syklawer E, Jakob JA, Bassett RL Jr, Curry JL, Gershenwald JE, Kim KB, Hwu P, Lazar AJ, Davies MA.

Cancer. 2013 Nov 1;119(21):3821-9. doi: 10.1002/cncr.28306. Epub 2013 Aug 6.

4.

BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival.

Akslen LA, Angelini S, Straume O, Bachmann IM, Molven A, Hemminki K, Kumar R.

J Invest Dermatol. 2005 Aug;125(2):312-7.

5.

Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort.

Si L, Kong Y, Xu X, Flaherty KT, Sheng X, Cui C, Chi Z, Li S, Mao L, Guo J.

Eur J Cancer. 2012 Jan;48(1):94-100. doi: 10.1016/j.ejca.2011.06.056. Epub 2011 Jul 23.

PMID:
21788131
6.

Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.

Ulivieri A, Cardillo G, Manente L, Paone G, Mancuso AP, Vigna L, Di Stasio E, Gasbarra R, Girlando S, Leone A.

Oncotarget. 2015 Aug 14;6(23):19868-79.

7.

The role of CCND1 alterations during the progression of cutaneous malignant melanoma.

Vízkeleti L, Ecsedi S, Rákosy Z, Orosz A, Lázár V, Emri G, Koroknai V, Kiss T, Ádány R, Balázs M.

Tumour Biol. 2012 Dec;33(6):2189-99. doi: 10.1007/s13277-012-0480-6. Epub 2012 Sep 23.

PMID:
23001925
8.

The role of BRAF mutations in primary melanoma growth rate and survival.

Mar VJ, Liu W, Devitt B, Wong SQ, Dobrovic A, McArthur GA, Wolfe R, Kelly JW.

Br J Dermatol. 2015 Jul;173(1):76-82. doi: 10.1111/bjd.13756. Epub 2015 Jun 13.

PMID:
25752325
9.

BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.

Barbour AP, Tang YH, Armour N, Dutton-Regester K, Krause L, Loffler KA, Lambie D, Burmeister B, Thomas J, Smithers BM, Hayward NK.

Eur J Cancer. 2014 Oct;50(15):2668-76. doi: 10.1016/j.ejca.2014.06.009. Epub 2014 Jul 25.

PMID:
25070294
10.

Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.

Moreau S, Saiag P, Aegerter P, Bosset D, Longvert C, Hélias-Rodzewicz Z, Marin C, Peschaud F, Chagnon S, Zimmermann U, Clerici T, Emile JF.

Ann Surg Oncol. 2012 Dec;19(13):4314-21. doi: 10.1245/s10434-012-2457-5. Epub 2012 Jul 7.

PMID:
22772867
11.

MicroRNA expression profiles associated with mutational status and survival in malignant melanoma.

Caramuta S, Egyházi S, Rodolfo M, Witten D, Hansson J, Larsson C, Lui WO.

J Invest Dermatol. 2010 Aug;130(8):2062-70. doi: 10.1038/jid.2010.63. Epub 2010 Apr 1.

12.

NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.

Edlundh-Rose E, Egyházi S, Omholt K, Månsson-Brahme E, Platz A, Hansson J, Lundeberg J.

Melanoma Res. 2006 Dec;16(6):471-8.

PMID:
17119447
13.

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.

Lee JH, Choi JW, Kim YS.

Br J Dermatol. 2011 Apr;164(4):776-84. doi: 10.1111/j.1365-2133.2010.10185.x. Epub 2011 Mar 21.

PMID:
21166657
14.

Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma.

Johansson CC, Egyházi S, Masucci G, Harlin H, Mougiakakos D, Poschke I, Nilsson B, Garberg L, Tuominen R, Linden D, Stolt MF, Hansson J, Kiessling R.

Cancer Immunol Immunother. 2009 Jul;58(7):1085-94. doi: 10.1007/s00262-008-0631-1. Epub 2008 Nov 28.

PMID:
19039588
15.

Association between BRAFV600E and NRASQ61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma.

Wu S, Kuo H, Li WQ, Canales AL, Han J, Qureshi AA.

Cancer Causes Control. 2014 Oct;25(10):1379-86. doi: 10.1007/s10552-014-0443-x. Epub 2014 Jul 22.

16.

Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma.

Lázár V, Ecsedi S, Szöllosi AG, Tóth R, Vízkeleti L, Rákosy Z, Bégány A, Adány R, Balázs M.

Mod Pathol. 2009 Oct;22(10):1367-78. doi: 10.1038/modpathol.2009.109. Epub 2009 Jul 24.

17.

Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.

Pozzobon FC, Puig-Butillé JA, González-Alvarez T, Carrera C, Aguilera P, Alos L, Badenas C, Grichnik JM, Malvehy J, Puig S.

Br J Dermatol. 2014 Oct;171(4):754-9. doi: 10.1111/bjd.13069. Epub 2014 Sep 10.

PMID:
24749938
18.

Melanoma prognostics and personalized therapeutics at a crossroad.

Lo RS.

J Invest Dermatol. 2013 Feb;133(2):292-5. doi: 10.1038/jid.2012.386.

19.

The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.

Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, Shih HA, Bangdiwala A, Shanley R, Lockney NA, Beal K, Lou E, Amatruda T, Sperduto WA, Kirkpatrick JP, Yeh N, Gaspar LE, Molitoris JK, Masucci L, Roberge D, Yu J, Chiang V, Mehta M.

Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1069-1077. doi: 10.1016/j.ijrobp.2017.03.030. Epub 2017 Mar 29.

PMID:
28721890
20.

Clinical correlates of NRAS and BRAF mutations in primary human melanoma.

Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EA.

Clin Cancer Res. 2011 Jan 15;17(2):229-35. doi: 10.1158/1078-0432.CCR-10-2276. Epub 2010 Oct 25. Erratum in: Clin Cancer Res. 2011 Mar 15;17(6):1641.

Supplemental Content

Support Center